Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

@article{Sos2009PredictingDS,
  title={Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.},
  author={Martin L Sos and Kathrin Michel and Thomas Zander and Jonathan J. Weiss and Peter Frommolt and Martin Peifer and Danan Li and Roland Ullrich and Mirjam Koker and Florian U. Fischer and Takeshi Shimamura and Daniel Rauh and Craig H. Mermel and Stefanie I. Fischer and Isabel St{\"u}ckrath and Stefanie Heynck and Rameen Beroukhim and William S. Lin and Wendy Winckler and Kinjal U. Shah and Thomas LaFramboise and Whei F. Moriarty and Megan C. Hanna and Laura Tolosi and J{\"o}rg Rahnenf{\"u}hrer and Roel G. W. Verhaak and Derek Y. Chiang and Gad Getz and Martin Hellmich and Juergen Wolf and Luc Girard and Michael T. Peyton and Barbara A. Weir and Tzu-Hsiu Chen and Heidi Greulich and Jordi G Barretina and Geoffrey I. Shapiro and Levi A. Garraway and A. F. Gazdar and John D. Minna and Matthew Meyerson and Kwok-kin Wong and Roman K. Thomas},
  journal={The Journal of clinical investigation},
  year={2009},
  volume={119 6},
  pages={
          1727-40
        }
}
Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 152 CITATIONS, ESTIMATED 54% COVERAGE

A combined tissue‐engineered/in silico signature tool patient stratification in lung cancer

  • Molecular oncology
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2009
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 3 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics.

  • Molecular cancer research : MCR
  • 2016
VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction

  • IEEE/ACM Transactions on Computational Biology and Bioinformatics
  • 2014
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Genetic modifiers of EGFR dependence in non-small cell lung cancer.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2014
VIEW 4 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

  • The Journal of experimental medicine
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 13 Highly Influenced Citations

  • Averaged 8 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment

E Ichihara
  • Proceedings of the 99th Annual Meeting of the American Association for Cancer Research
  • 2008

Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2008

Major response to imatinib mesylate in KIT-mutated melanoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008